Researchers have identified several new genes responsible for Alzheimer’s disease (AD) including those leading to functional and structural changes in the brain and elevated levels of AD proteins in cerebrospinal fluid (CSF).
Some researchers at Montana State University have a light touch when it comes to unraveling the mysteries of the brain and exploring new ways to treat diseases like Alzheimer’s.
One third of all drugs on the American market act on the same kind of important cell receptor – the G protein-coupled receptors. A major mapping of these drugs by the University of Copenhagen and Uppsala University found that their pharmacological mechanisms are becoming more complex. The mapping also reveals rapid developments especially within Alzheimer’s disease, obesity, asthma and diabetes.
Study suggests Alzheimer’s Disease and Type 2 diabetes might both be the price of a longer lifespan, with altered insulin function the common cause. A review led by Professor Simon Lovestone, an old age psychiatrist from Oxford Health NHS Foundation Trust, found that humans were almost unique in having Alzheimer’s Disease.